Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6.

The ability of antipsychotic drugs to inhibit the catalytic activity of five cytochrome P-450 (CYP) isoforms was compared using in vitro human liver microsomal preparations to evaluate the relative potential of these drugs to inhibit drug metabolism. The apparent kinetic parameters for enzyme inhibition were determined by nonlinear regression analysis of the data. All antipsychotic drugs tested competitively inhibited dextromethorphan O-demethylation, a selective marker for CYP2D6, in a concentration-dependent manner. Thioridazine and perphenazine were the most potent, with IC(50) values (2.7 and 1.5 microM) that were comparable to that of quinidine (0.52 microM). The estimated K(i) values for CYP2D6-catalyzing dextrorphan formation were ranked in the following order: perphenazine (0.8 microM), thioridazine (1.4 microM), chlorpromazine (6.4 microM), haloperidol (7.2 microM), fluphenazine (9.4 microM), risperidone (21.9 microM), clozapine (39.0 microM), and cis-thiothixene (65.0 microM). No remarkable inhibition of other CYP isoforms was observed except for moderate inhibition of CYP1A2-catalyzed phenacetin O-deethylation by fluphenazine (K(i) = 40.2 microM) and perphenazine (K(i) = 65.1). The estimated K(i) values for the inhibition of CYP2C9, 2C19, and 3A were >300 microM in almost all antipsychotics tested. These results suggest that antipsychotic drugs exhibit a striking selectivity for CYP2D6 compared with other CYP isoforms. This may reflect a remarkable commonality of structure between the therapeutic targets for these drugs, the transporters, and metabolic enzymes that distribute and eliminate them. Clinically, coadministration of these medicines with drugs that are primarily metabolized by CYP2D6 may result in significant drug interactions.

[1]  D. Flockhart,et al.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[2]  G. L. Maynard,et al.  Thioridazine interferences with imipramine metabolism and measurement. , 1996, Therapeutic drug monitoring.

[3]  S. Wrighton,et al.  Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[4]  R. Tyndale,et al.  The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. , 1990, Archives of biochemistry and biophysics.

[5]  D. Goff,et al.  Clinically Significant Interactions of Psychotropic Agents with Antipsychotic Drugs , 1996, Drug safety.

[6]  Elizabeth Landrum Michalets,et al.  Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.

[7]  P. Jatlow,et al.  Neuroloeptic effect on desipramine steady-state plasma concentratins. , 1980, The American journal of psychiatry.

[8]  F. Belpaire,et al.  Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. , 2003, British journal of clinical pharmacology.

[9]  F. Guengerich,et al.  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.

[10]  L. Benet,et al.  Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[11]  J. Hallas,et al.  Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out-patients--a prescription database study. , 1994, British journal of clinical pharmacology.

[12]  T. Henthorn,et al.  Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. , 1985, Biochemical pharmacology.

[13]  L. Pickle,et al.  The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study , 1995, Clinical pharmacology and therapeutics.

[14]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[15]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.

[16]  P. Bechtel,et al.  Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. , 1989, British journal of clinical pharmacology.

[17]  D. Flockhart,et al.  Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6) , 1999, Clinical pharmacology and therapeutics.

[18]  L. Ereshefsky.  Pharmacokinetics and drug interactions: update for new antipsychotics. , 1996, The Journal of clinical psychiatry.

[19]  D. Flockhart,et al.  Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. , 1998, The Journal of pharmacology and experimental therapeutics.

[20]  D. Goff,et al.  Drug interactions with antipsychotic agents. , 1993, Journal of clinical psychopharmacology.

[21]  I. H. Segel.  Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .

[22]  D. Cohen,et al.  The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[23]  L. Gottschalk,et al.  Distribution of thioridazine and its metabolites in human tissues and fluids obtained postmortem. , 1978, Clinical chemistry.

[24]  H. Pollard,et al.  Application of Bradford's protein assay to adrenal gland subcellular fractions. , 1978, Analytical biochemistry.

[25]  S. Imaoka,et al.  Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. , 1997, Biochemical pharmacology.

[26]  B. Pollock,et al.  The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. , 1997, Journal of clinical psychopharmacology.

[27]  D A Smith,et al.  An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. , 1995, British journal of clinical pharmacology.

[28]  J. Javaid,et al.  Clinical Pharmacokinetics of Antipsychotics , 1994, Journal of clinical pharmacology.

[29]  T. Smith,et al.  Effect of Clozapine on Plasma Nortriptyline Concentration , 1994, Pharmacopsychiatry.

[30]  L. Bertilsson,et al.  The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. , 2003, British journal of clinical pharmacology.

[31]  G. Tucker,et al.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. , 1988, The Journal of pharmacology and experimental therapeutics.

[32]  S. Binkley,et al.  In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. , 1996, British journal of clinical pharmacology.

[33]  M. Relling,et al.  Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. , 1990, The Journal of pharmacology and experimental therapeutics.

[34]  G. Pacifici,et al.  Advances in Drug Metabolism in Man , 1995 .

[35]  M. Murray,et al.  In vitro inhibition of hepatic drug oxidation by thioridazine. Kinetic analysis of the inhibition of cytochrome P-450 isoform-specific reactions. , 1989, Biochemical pharmacology.

[36]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[37]  G. Bates,et al.  Cytochromes and psychotropic drug interactions , 1996, British Journal of Psychiatry.

[38]  R. Tukey,et al.  Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. , 1993, The Journal of pharmacology and experimental therapeutics.

[39]  R. Tyndale,et al.  Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. , 1991, Molecular pharmacology.